w******9
发帖数: 1604 | | b***y
发帖数: 14281 | 2 歧视。
★ 发自iPhone App: ChineseWeb 13
【在 w******9 的大作中提到】
: 。。。
| l*******1
发帖数: 16217 | | b***y
发帖数: 14281 | 4 那个张姓没这个张姓华人的瓷实，这个好歹国内念过大学。
【在 l*******1 的大作中提到】
: 化学奖还有另一张姓华人看会不会中
| l*******1
发帖数: 16217 | | l*******1
发帖数: 16217 | 6 CRISPR 这个绝对该得，我刚才查了一下 中国和美国FDA 今年已经批准肺癌试验了，前
面英国的报道过治愈过白血病，
The Chinese trial will enrol patients who have metastatic non-small cell
lung cancer and for whom chemotherapy, radiation therapy and other
treatments have failed. “Treatment options are very limited,” says Lu. “
This technique is of great promise in bringing benefits to patients,
especially the cancer patients whom we treat every day.”
Leukaemia success heralds wave of gene-editing therapies
Lu’s team will extract immune cells called T cells from the blood of the
enrolled patients, and then use CRISPR–Cas9 technology — which pairs a
molecular guide able to identify specific genetic sequences on a chromosome
with an enzyme that can snip the chromosome at that spot — to knock out a
gene in the cells. The gene encodes a protein called PD-1 that normally acts
as a check on the cell’s capacity to launch an immune response, to prevent
it from attacking healthy cells.
The gene-edited cells will then be multiplied in the lab and re-introduced
into the patient’s bloodstream. The engineered cells will circulate and,
the team hopes, home in on the cancer, says Lu. The planned US trial
similarly intends to knock out the gene for PD-1, and it will also knock out
a second gene and insert a third before the cells are re-introduced into
the patient.
Last year, the FDA approved for use against lung cancer two antibody-based
therapies that block PD-1. But it is difficult to predict for any given
patient to what extent these antibodies will block PD-1 and activate the
immune response.
Gene-editing research in human embryos gains momentum
By contrast, knocking out the gene blocks PD-1 with greater certainty, while
multiplying the cells increases the chance of a response. “It will be much
more powerful than the antibodies," says Timothy Chan, who does clinical
research in immunotherapy at Memorial Sloan Kettering Cancer Center in New
York City. |
|
